Decreased Mortality in Users of Estrogen Replacement Therapy

Archives of Internal Medicine

Volumn 151, Issue 1, 1991, Pages 75-78

  Henderson, Brian E ^a   Paganini Hill, Annlia ^a   Ross, Ronald K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN;

ADULT; ARTICLE; CAUSE OF DEATH; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; CALIFORNIA; CAUSE OF DEATH; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMAN; MENOPAUSE; NEOPLASMS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026016029     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1991.00400010095012     Document Type: Article

References (26)

1. World Health Organization. Research on the menopause. WHO Tech Rep Ser. 1981;670:7-120.
2. Hoover R, Gray LA, Cole P, MacMahon P. Menopausal estrogens and breast cancer. N Engl J Med. 1976;295:401-405.
3. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980;243:1635-1639.
4. Brinton LA, Hoover R, Fraumeni JF. Menopausal estrogens and breast cancer risk: an expanded case-control study. Br J Cancer. 1986;54:825-832.
5. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med. 1989;321:293-297.
6. Henderson BE, Ross RK, Lobo RA, Pike MC, Mack TM. Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril. 1988;49:9s-15s.
7. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Meno pausal oestrogen therapy and protection from ischemic heart disease. Lancet. 1981;1:858-860.
8. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol. 1986;154:1181-1186.
9. Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc. 1983;78:1-12.
10. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health related information. Am J Epidemiol. 1982;116:114-122.
11. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement thera py and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312-317.
12. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women. Circulation. 1987;75:1102-1109.
13. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FC, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coro nary heart disease. N Engl J Med. 1985;313:1044-1049.
14. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garbard C. Postmenopausal estrogen use and mortality. Am J Epidemiol. 1988;128:606-614.
15. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987;94:620-635.
16. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med. 1985;313:1038-1043.
17. Burch JC, Byrd BF, Vaughn WK. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol. 1974;118:778-782.
18. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
19. Petitti DB, Perlman JA, Sidney S. Postmenopausal estrogen use and heart disease. N Engl J Med. 1986;315:131-132.
20. Bush JL, Miller VT. Effects of pharmacologic agents used during meno pause: impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause, Physiology and Pharmacology. Chicago, Ill: Mosby-Year Book Medical Pub lishers Inc; 1987:187-208.
21. Wahl P, Walden C, Knopp R. Effect of estrogen/progestin potency on lipid and lipoprotein cholesterol. N Engl J Med. 1983;308:862-867.
22. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s: Rancho Bernardo, California revisited. JAMA. 1989;261:2095-2100.
23. Pitt B, Shea MJ, Ramson JL, Lucchesi BR. Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med. 1983;99:83-93.
24. Ylikorkala O, Puolakka J, Vrinikka L. Vasoconstrictory thromboxane A2 and vasodilatory prostacyclin in climacteric women: effect of oestrogen-progestogen therapy. Maturitas. 1984;5:201-205.
25. Mileikowsky GN, Nadler JL, Huey F, Francis R, Roy S. Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives. Am J Obstet Gynecol. 1988;159:1547-1552.
26. Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prog nosis after breast cancer diagnosis in women exposed to estrogen and estrogenprogestogen replacement therapy. Am J Epidemiol. 1989;130:221-228.